Voxar rebrands 3D product at ECR
Scottish software developer Voxar launched at the ECR a newly rebranded upgrade of its flagship 3D software, Voxar 3D. The new release, version 4.1, introduces a task-based user interface and workflow improvements. The company also showcased its new
Scottish software developer Voxar launched at the ECR a newly rebranded upgrade of its flagship 3D software, Voxar 3D. The new release, version 4.1, introduces a task-based user interface and workflow improvements. The company also showcased its new release of Voxar Colonscreen, version 2.2, and announced details of its new concurrent licensing scheme for Europe. Concurrent licenses allow operators to distribute and postprocess images on multiple machines across a hospital's DICOM network.
Can MRI-Guided Transurethral Ultrasound Ablation Have an Impact for Localized Prostate Cancer?
December 11th 2023Follow-up MRI imaging one year after transurethral ultrasound ablation revealed approximately 50 percent decreases in prostate volume and median PSA density, according to recently presented research findings at the 2023 Society of Urologic Oncology (SUO) Annual Meeting.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
What a New Study Reveals About Adjunctive DBT and Early-Stage Invasive Breast Cancer
December 6th 2023The combination of digital breast tomosynthesis (DBT) and digital mammography had a 21.6 higher invasive breast cancer detection rate for stage 1 tumors than digital mammography alone, according to a new study involving nearly 100,000 women.
